NATIVE GENE THERAPY Trademark

Trademark Overview

On Monday, October 18, 2021, a trademark application was filed for NATIVE GENE THERAPY with the United States Patent and Trademark Office. The USPTO has given the NATIVE GENE THERAPY trademark a serial number of 97079718. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, June 15, 2023. This trademark is owned by Omega Therapeutics, Inc.. The NATIVE GENE THERAPY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical agents that target DNA structure to treat various diseases, namely, monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease
native gene therapy

General Information

Serial Number97079718
Word MarkNATIVE GENE THERAPY
Filing DateMonday, October 18, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, June 15, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical agents that target DNA structure to treat various diseases, namely, monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease
NOT AVAILABLE"GENE THERAPY"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, November 4, 2021
Primary Code005
First Use Anywhere DateThursday, January 1, 1970
First Use In Commerce DateThursday, January 1, 1970

Trademark Owner History

Party NameOmega Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, US 02140

Trademark Events

Event DateEvent Description
Thursday, October 21, 2021NEW APPLICATION ENTERED
Thursday, November 4, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 13, 2021ASSIGNED TO EXAMINER
Wednesday, December 22, 2021NON-FINAL ACTION WRITTEN
Wednesday, December 22, 2021NON-FINAL ACTION E-MAILED
Wednesday, December 22, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 7, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 7, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 8, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, April 17, 2022NON-FINAL ACTION WRITTEN
Sunday, April 17, 2022NON-FINAL ACTION E-MAILED
Sunday, April 17, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 17, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 17, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 1, 2022FINAL REFUSAL WRITTEN
Thursday, December 1, 2022FINAL REFUSAL E-MAILED
Thursday, December 1, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, June 15, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, June 15, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Thursday, June 15, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND

Related Keywords

therapy gene native disease diseases channelopathies hepatic bone haploinsufficiencies endocrine cardiovascular skeletal renal